Estriol & Cognition in Multiple Sclerosis
Brief Description Of Study
The purpose of this study is to determine whether the combination of treatment with available MS therpies and estriol has an effect on cognitive function and disease activity and outcomes.
Detailed Study Description
Eligible participants include women with all forms of Multiple Sclerosis on a stable dose of FDA approved MS therapy for 90 days or more. Patients may be off MS therapy, but also for 90 days or more and medically stable. Participants must be able to walk 330 feet without rest (unilateral assistance, such as a cane is allowed). Males are not eligible to participate.